Cogent Biosciences Inc

Change company Symbol lookup

Select an option...

COGT Cogent Biosciences Inc

KINS Kingstone Companies Inc

PBI Pitney Bowes Inc

VRRM Verra Mobility Corp

VGI Virtus Global Multi-Sector Income Fund

FATH Fathom Digital Manufacturing Corp

$NQUSL50206015GBPN Nasdaq Large Cap Commercial Vehicles

BTSR Brightstar Information Technology Group Inc

RL Ralph Lauren Corp

FOXA Fox Corp

Go

Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company’s advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17 found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The Company has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.